首页> 外国专利> THE UNIT WITH THE INCREASED CAPACITY TO THE DEFORMATION CONTAINING AREA OF THE DISCIPLES ARE MEATED BY MEASURING AREA TO THE BEST PENETRATION THROUGH THE SEMI-PERMEABLE BARRIERS AND FOR THE HYDROPHYSICAL DEVELOPMENT UNDER THE CAPACITY.

THE UNIT WITH THE INCREASED CAPACITY TO THE DEFORMATION CONTAINING AREA OF THE DISCIPLES ARE MEATED BY MEASURING AREA TO THE BEST PENETRATION THROUGH THE SEMI-PERMEABLE BARRIERS AND FOR THE HYDROPHYSICAL DEVELOPMENT UNDER THE CAPACITY.

机译:通过对穿过半透明障碍物的最佳渗透区域进行测量,并针对该能力下的水物理开发,对具有较大变形能力的单元进行测量。

摘要

This invention relates to a combination of at least three amphipathic compounds forming a suspension of aggregates in a polar liquid. Careful selection of compounds for the unit, the solubility of which varies at least two, or even ten times, ensures that these units have a wide, unusually plastic surface. This is probably achieved by simultaneously exposing the aggregate to at least two of the most soluble compounds among the three components of the combination mentioned, at least one of which is the active ingredient, preferably a drug; the third component, alternatively, can also serve as a drug. The present invention also relates to the use of these aggregates in pharmaceutical preparations intended for the delivery of drugs into the blood of warm-blooded animals. This becomes possible due to the high drug saturation of these aggregates having an extremely flexible and elastic surface, which contributes to the high adaptogenicity of the final drug carriers. The invention further relates to suitable methods and preferred conditions for the manufacture and use of carriers. The present invention also describes new formulations of non-steroidal anti-inflammatory drugs (NSAIDs) based on mixed aggregates containing at least three amphipathic compounds soluble in a suitable, for example pharmaceutically available, polar liquid medium. The international application was published with the report
机译:本发明涉及在极性液体中形成聚集体悬浮液的至少三种两亲化合物的组合。仔细选择单元的化合物(其溶解度至少变化两倍,甚至十倍),可确保这些单元具有较宽的,异常塑料的表面。这可能是通过将聚集体同时暴露于上述组合的三种成分中的至少两种最易溶的化合物中来实现的,其中至少一种是活性成分,优选药物;第三组分也可以用作药物。本发明还涉及这些聚集体在用于将药物递送到温血动物血液中的药物制剂中的用途。由于这些聚集体具有极高的柔韧性和弹性表面而使药物高度饱和,因此这成为可能,这有助于最终药物载体的高度适应性。本发明还涉及载体的制造和使用的合适方法和优选条件。本发明还描述了非甾体抗炎药(NSAID)的新制剂,其基于含有至少三种可溶于合适的,例如可药用的极性液体介质中的两亲化合物的混合聚集体。国际申请与报告一同发布

著录项

  • 公开/公告号EA200500632A1

    专利类型

  • 公开/公告日2005-12-29

    原文格式PDF

  • 申请/专利权人 ИДЕА АГ;

    申请/专利号EA20050000632

  • 申请日2003-10-09

  • 分类号A61K9/107;A61K9;A61K9/127;A61K31/192;A61K31/195;A61K31/196;A61K31/405;A61K31/5415;A61K47/10;A61K47/16;A61K47/24;A61K47/26;A61K47/34;A61K47/44;A61P29;H04B7/005;

  • 国家 EA

  • 入库时间 2022-08-21 21:39:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号